Servier Drug Risk Trial Suspended After Challenge, France 3 Says

Les Laboratoires Servier and its founder won their bid to suspend a trial over claims they hid the risks of a diabetes drug, when a judge ruled their constitutional challenge to the process was serious enough to merit a higher court’s review, France 3 reported today, citing the judge.

A procedural hearing is planned for Dec. 14 to reschedule the trial, pending the outcome of the constitutional review, France 3 said on its website.

To contact the reporter on this story: Heather Smith in Paris at hsmith26@bloomberg.net

To contact the editor responsible for this story: Anthony Aarons at aaarons@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.